{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:10Z","timestamp":1789632190217,"version":"build-2803163510"},"reference-count":48,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15812","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T10:29:06Z","timestamp":1786530546000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy combined with anti\u2011angiogenic therapy, radiotherapy and chemotherapy for the treatment of giant pelvic osteosarcoma: A case report and literature review"],"prefix":"10.3892","volume":"32","author":[{"given":"Qingying","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yefeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang 310009, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"key20260917101244_b1-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1327459","DOI":"10.3389\/fmolb.2024.1327459","article-title":"Emerging roles of long non-coding RNAs in osteosarcoma","volume":"11","author":"Liao","year":"2024","journal-title":"Front Mol Biosci"},{"key":"key20260917101244_b2-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/cells11213507","article-title":"Current Status and Prospects of Targeted Therapy for Osteosarcoma","volume":"11","author":"Hu","year":"2022","journal-title":"Cells"},{"key":"key20260917101244_b3-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20260917101244_b4-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"key20260917101244_b5-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2106\/00004623-199274030-00002","article-title":"Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients","volume":"74","author":"Fahey","year":"1992","journal-title":"J Bone Joint Surg Am"},{"key":"key20260917101244_b6-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s40001-025-02599-z","article-title":"Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: An analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrogate endpoint","volume":"30","author":"Liu","year":"2025","journal-title":"Eur J Med Res"},{"key":"key20260917101244_b7-ol-32-4-15812","article-title":"Correlation between prognostic factors and the histopathological response to neoadjuvant chemotherapy in osteosarcoma: A retrospective study","author":"Prabowo","year":"2021","journal-title":"Int J Surg Oncol"},{"key":"key20260917101244_b8-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"8027314","DOI":"10.1155\/2021\/8027314","article-title":"Osteosarcoma of the Pelvis: Clinical presentation and overall survival","volume":"2021","author":"Brown","year":"2021","journal-title":"Sarcoma"},{"key":"key20260917101244_b9-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s13018-023-04326-y","article-title":"Survival benefits and challenges of adjuvant chemotherapy for high-grade osteosarcoma: A population-based study","volume":"18","author":"Wang","year":"2023","journal-title":"J Orthop Surg Res"},{"key":"key20260917101244_b10-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5704\/MOJ.1303.018","article-title":"Outcome of surgical treatment of pelvic osteosarcoma: hospital universiti sains malaysia experience","volume":"7","author":"Ariff","year":"2013","journal-title":"Malays Orthop J"},{"key":"key20260917101244_b11-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/cells10010172","article-title":"Future directions in the treatment of osteosarcoma","volume":"10","author":"Smrke","year":"2021","journal-title":"Cells"},{"key":"key20260917101244_b12-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/230949900801600211","article-title":"Tumour volume and lung metastasis in patients with osteosarcoma","volume":"16","author":"Munajat","year":"2008","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"key20260917101244_b13-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1245\/s10434-010-1536-8","article-title":"Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma","volume":"18","author":"Song","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"key20260917101244_b14-ol-32-4-15812","first-page":"14","article-title":"Primary osteogenic sarcoma: Pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement","volume":"101","author":"Huvos","year":"1977","journal-title":"Arch Pathol Lab Med"},{"key":"key20260917101244_b15-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1080\/02648725.2022.2163805","article-title":"The relationship between adjuvant radiotherapy and survival of osteosarcoma: A case-control study","volume":"39","author":"Zhang J","year":"2023","journal-title":"Biotechnol Genet Eng Rev"},{"key":"key20260917101244_b16-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00402-020-03494-4","article-title":"The effect of preoperative radiotherapy on local control and prognosis in high-grade non-metastatic intramedullary osteosarcoma of the extremities","volume":"141","author":"Hiz","year":"2021","journal-title":"Arch Orthop Trauma Surg"},{"key":"key20260917101244_b17-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/cells10020366","article-title":"Radiotherapy in the management of pediatric and adult osteosarcomas: A multi-institutional cohort Analysis","volume":"10","author":"Spalek","year":"2021","journal-title":"Cells"},{"key":"key20260917101244_b18-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2007.06.155","article-title":"Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR\/Flk-1 of endothelial cells","volume":"361","author":"Ling","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"key20260917101244_b19-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bone.2013.07.035","article-title":"Effects of endostar combined multidrug chemotherapy in osteosarcoma","volume":"57","author":"Xu","year":"2013","journal-title":"Bone"},{"key":"key20260917101244_b20-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"e9077","DOI":"10.1097\/MD.0000000000009077","article-title":"Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report","volume":"96","author":"Jiang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"key20260917101244_b21-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41419-022-04620-3","article-title":"Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"key20260917101244_b22-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"864790","DOI":"10.3389\/fonc.2022.864790","article-title":"Bevacizumab, with sorafenib and cyclophosphamide provides clinical benefit for recurrent or refractory osseous sarcomas in children and young adults","volume":"12","author":"Bodea","year":"2022","journal-title":"Front Oncol"},{"key":"key20260917101244_b23-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"e13102","DOI":"10.1111\/cpr.13102","article-title":"Current research progress in targeted anti-angiogenesis therapy for osteosarcoma","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"key20260917101244_b24-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann Oncol"},{"key":"key20260917101244_b25-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20260917101244_b26-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/0284186X.2018.1503714","article-title":"Pazopanib in relapsed osteosarcoma patients: Report on 15 cases","volume":"58","author":"Longhi","year":"2019","journal-title":"Acta Oncol"},{"key":"key20260917101244_b27-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","article-title":"Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial","volume":"24","author":"Xie","year":"2019","journal-title":"Oncologist"},{"key":"key20260917101244_b28-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20260917101244_b29-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20260917101244_b30-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2147\/CMAR.S378264","article-title":"The Combination of Anlotinib and Gemcitabine\/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy","volume":"14","author":"Wang","year":"2022","journal-title":"Cancer Manag Res"},{"key":"key20260917101244_b31-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/ijc.32180","article-title":"Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma","volume":"145","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"key":"key20260917101244_b32-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study","volume":"119","author":"Le Cesne","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20260917101244_b33-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/s41467-022-30874-8","article-title":"Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma","volume":"13","author":"D'Angelo","year":"2022","journal-title":"Nat Commun"},{"key":"key20260917101244_b34-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: First approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"key20260917101244_b35-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1502945","DOI":"10.3389\/fonc.2024.1502945","article-title":"Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: Findings from a single-center retrospective study","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"key20260917101244_b36-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40265-021-01508-y","article-title":"Penpulimab: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"key20260917101244_b37-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","article-title":"First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): A multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial","volume":"12","author":"Zhong","year":"2024","journal-title":"Lancet Respir Med"},{"key":"key20260917101244_b38-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cpt.2024.02.001","article-title":"Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial","volume":"2","author":"Zhang","year":"2024","journal-title":"Cancer Pathog Ther"},{"key":"key20260917101244_b39-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"846597","DOI":"10.3389\/fonc.2022.846597","article-title":"Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"key20260917101244_b40-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/jso.23076","article-title":"Outcome of surgical treatment of pelvic osteosarcoma","volume":"106","author":"Guo","year":"2012","journal-title":"J Surg Oncol"},{"key":"key20260917101244_b41-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1200\/JCO.2003.01.142","article-title":"Osteosarcoma of the pelvis: Experience of the cooperative osteosarcoma study group","volume":"21","author":"Ozaki","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20260917101244_b42-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.3390\/cancers13133320","article-title":"Impact of surgical resection and reasons for poor prognosis of pelvic osteosarcoma based on the bone tumor registry in Japan","volume":"12","author":"Takenaka","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260917101244_b43-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0339","article-title":"Constructing a nomogram for predicting pelvic osteosarcoma: A retrospective study based on the SEER database and a chinese cohort","volume":"85","author":"Xu","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"key20260917101244_b44-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s12013-014-0314-9","article-title":"High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma","volume":"71","author":"Liu","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"key20260917101244_b45-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"e250017","DOI":"10.6004\/jnccn.2025.0017","article-title":"Bone cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260917101244_b46-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-24-1339","article-title":"Phase II Trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma with serial monitoring using liquid biopsy: A report from the national pediatric cancer foundation","volume":"30","author":"Dhir","year":"2024","journal-title":"Clin Cancer Res"},{"key":"key20260917101244_b47-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.2147\/DDDT.S426898","article-title":"Research progress on mechanism and management of adverse drug reactions of Anlotinib","volume":"17","author":"Li","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"key20260917101244_b48-ol-32-4-15812","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2484\/rcr.v8i3.864","article-title":"Venous tumor thrombus from a pelvic osteosarcoma","volume":"8","author":"Mitsunaga","year":"2013","journal-title":"Radiol Case Rep"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:13:27Z","timestamp":1789629207000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,12]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15812","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}